Value
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 6.9 |
| P/S | 9.2 |
| EV/EBITDA | 2.3 |
| Fwd P/E | 7.7 |
| PEG | 5.0 |
| Analyst target | 5.0 |
- ▸Forward P/E: 15.9x
- ▸PEG: 1.53
BVS · Why this verdict
Why Bioventus (BVS) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.6/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
BVS's beat-heavy earnings track record and attractive valuation are balanced against overbought technical conditions and unusually elevated options hedging ahead of its next report.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The put/call ratio stands at an elevated 16.50 and implied volatility at 115%, indicating the options market is pricing significant downside hedging or a big expected move. Options | The put/call ratio should normalize toward 1.0 or below over the next 12 months if downside hedging pressure eases. | ↑Improving |
| CounterA high put/call ratio on a small-float healthcare name can be driven by a handful of large hedges rather than broad market sentiment, and doesn't necessarily predict price direction. | ||
The company has beaten earnings estimates in three of its last four quarters, with an average surprise of about 42%, reflecting consistent execution. Earnings | The beat streak should continue, with the company beating or meeting estimates at its next earnings report on 2026-08-04. | ↓Deteriorating |
| CounterA string of earnings beats often triggers guidance resets that make future beats harder to sustain, especially with the stock already at overbought technical levels. | ||
The stock trades at an attractive valuation, with a forward P/E of 11.6x and a PEG ratio of 1.27, alongside a 222% free-cash-flow-to-net-income conversion rate. Valuation breakdown | The valuation multiple should expand toward peer averages over the next 12 months if the market recognizes the mispricing. | ↓Deteriorating |
| CounterThe stock also carries a Rule of 40 failure at 18 versus the 40 target, suggesting the low valuation could be justified by weaker combined growth-plus-profitability. | ||
The stock is technically overbought with an RSI of 78, even as it remains above its 200-day moving average with accumulating volume. Momentum breakdown | RSI should cool back into a neutral 40-60 range without a sharp price correction over the next few months. | ↓Deteriorating |
| CounterPersistent overbought conditions in a strong uptrend name are common and don't always precede a correction, especially with earnings as an ongoing catalyst. | ||
The put/call ratio stands at an elevated 16.50 and implied volatility at 115%, indicating the options market is pricing significant downside hedging or a big expected move.
↑ImprovingOptions
- Expectation
- The put/call ratio should normalize toward 1.0 or below over the next 12 months if downside hedging pressure eases.
CounterA high put/call ratio on a small-float healthcare name can be driven by a handful of large hedges rather than broad market sentiment, and doesn't necessarily predict price direction.
The company has beaten earnings estimates in three of its last four quarters, with an average surprise of about 42%, reflecting consistent execution.
↓DeterioratingEarnings
- Expectation
- The beat streak should continue, with the company beating or meeting estimates at its next earnings report on 2026-08-04.
CounterA string of earnings beats often triggers guidance resets that make future beats harder to sustain, especially with the stock already at overbought technical levels.
The stock trades at an attractive valuation, with a forward P/E of 11.6x and a PEG ratio of 1.27, alongside a 222% free-cash-flow-to-net-income conversion rate.
↓DeterioratingValuation breakdown
- Expectation
- The valuation multiple should expand toward peer averages over the next 12 months if the market recognizes the mispricing.
CounterThe stock also carries a Rule of 40 failure at 18 versus the 40 target, suggesting the low valuation could be justified by weaker combined growth-plus-profitability.
The stock is technically overbought with an RSI of 78, even as it remains above its 200-day moving average with accumulating volume.
↓DeterioratingMomentum breakdown
- Expectation
- RSI should cool back into a neutral 40-60 range without a sharp price correction over the next few months.
CounterPersistent overbought conditions in a strong uptrend name are common and don't always precede a correction, especially with earnings as an ongoing catalyst.
Per-dimension breakdown
Quality
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 8.6 |
| ROA | 3.7 |
| Gross margin | 9.7 |
| Op margin | 4.9 |
| Net margin | 4.7 |
| Current ratio | 6.1 |
| FCF quality | 9.1 |
| Moat | 6.4 |
| Rule of 40 | 3.0 |
| Piotroski F | 8.9 |
- ▸Excellent ROE: 26%
- ▸Excellent cash conversion: 124% FCF/NI
- ▸Rule of 40: 15 (fail)
- ▸Strong Piotroski F-Score: 8/9
Growth
3.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 3.5 |
Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.4 |
| MACD | 9.1 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 6.6 |
- ▸Overbought (RSI 73)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 7.7 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 20%
Insider
7.1/10data confidence 50%| Component | Sub-score |
|---|---|
| holder change | 7.2 |
| notable moves | 7.0 |
- ▸Insider dollar basis unavailable — not scored
Peer rank
4.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.0 |
| quality rank | 8.0 |
| growth rank | 2.0 |
- ▸Superior ROE vs peers
Technical
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.8 |
| support resistance | 2.4 |
| 52w position | 8.4 |
Risk (lower is worse)
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.6 |
| days to cover | 2.7 |
| volatility | 3.5 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 9.1 |
| debt equity | 5.3 |
- ▸High IV: 90%
- ▸Concentration risks: 2 MED (10-K Item 1A)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/0M
- ▸Earnings in 4 days
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (5)
- MOMENTUM:6.0>=5.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:0.3<1.5@spot
- EARNINGS_PROXIMITY:4d<=7d
Warning (0)
none
Insider data unavailable
Reward-to-Risk
0.31
Upside
+4.5%
Downside
14.5%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $1.0B<$5B
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:6.0>=5.5. Top dim: Insider at 7.1; weakest: Growth at 3.5. No conviction either direction.
The strongest dimensions are Insider at 7.1, Catalyst at 7.0, and Quality at 6.5; the weakest are Growth at 3.5, Technical at 4.2, and Peer rank at 4.9. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 0.31 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Earnings Beat Streak
Trip ifEPS surprise falls below 0% (a miss) in 2 consecutive quarters.
- P2Attractive Valuation
Trip ifStock price falls more than 10% from the current $10.48 level.
- P3Overbought Momentum Risk
Trip ifStock price falls more than 15% from the current $10.48 level within 3 months, confirming an overbought reversal.
- P4Elevated Put Call Hedging
Trip ifPut/call ratio falls below 2.0 from its current 16.50 reading.